- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07584239
Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial
LiveWellLung: A Prehabilitation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery (ROAR-LCS) With Biospecimen Collection
Visão geral do estudo
Status
Intervenção / Tratamento
- Procedimento: Coleta de bioespécimes
- Outro: Administração de pesquisas
- Outro: Exercise Intervention
- Outro: Exercise Intervention
- Outro: Exercise Intervention
- Procedimento: Physical Therapy
- Comportamental: Relaxation Technique
- Outro: Internet-Based Intervention
- Outro: Text Message-Based Navigation Intervention
Descrição detalhada
PRIMARY OBJECTIVE:
I. To evaluate feasibility of the two peri-operative programs, as defined by participant adherence and retention rates within their respective interventions.
EXPLORATORY OBJECTIVE:
I. Associating gut microbiome diversity and T cell senescence profiles (peripheral blood) at baseline and end of study as potential biomarkers of treatment-related toxicity and tumor response to treatment among other clinical secondary outcomes (e.g. surgical complications, overall survival).
OUTLINE: Patients choose which arm (I or II) they would like to participate in, depending upon availability.
ARM I (ROAR-LCS): Patients complete in person physical therapy sessions during weeks with regularly scheduled clinic visits, at first session after surgery, and the final session. These sessions include 10 minutes of a cardiovascular warm up followed up core exercise and resistance training. Patients also complete virtual physical therapy sessions in a similar fashion during weeks in between regularly scheduled clinic visits. Patients complete 6-8 sessions prior to surgery and 12 sessions total (over 3-4 months). Patients receive a portable exercise peddler and resistance bands for at home exercise. Patients complete the exercises at home as instructed during their sessions, at first weekly then increased to twice then three times weekly depending upon tolerance. Patients also complete progressive muscle relaxation exercises during a guided virtual session once weekly and at home individually 3-5 times per week. Patients also undergo blood sample collection on study.
ARM II (BeFitMe): Patients receive access to the BeFitMe application (app) on their smartphone and an Apple watch and exercise flip book for 9 months. Patients are assigned exercises, lasting at least 3 minutes, and receive access to self guided exercise videos. Patients receive motivational text messages to encourage their completion of the exercises once daily. Patients track their exercise and step counts using the app. Patients also undergo blood sample collection on study.
After completion of study intervention, patients are followed up at 1 and 2 years.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: The Ohio State University Comprehensive Cancer Center
- Número de telefone: 800-293-5066
- E-mail: OSUCCCClinicaltrials@osumc.edu
Locais de estudo
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- Ohio State University Comprehensive Cancer Center
-
Contato:
- Carolyn J. Presley, MD
- Número de telefone: 614-293-6453
- E-mail: carolyn.presley@osumc.edu
-
Investigador principal:
- Carolyn J. Presley, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosed with: potentially resectable non small cell lung cancer (NSCLC) stage (9th edition: IB-IIIB)
- Intent to receive surgery following neoadjuvant systemic therapy from the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic
- Patients who are at least 6 weeks out of the surgery date are eligible to participate
- Willingness to participate and adhere to the study intervention program
- Ability to understand and willingness to sign an informed consent document
Exclusion Criteria:
- Prisoners are excluded from participation
- There is NO exclusion criteria pertaining to Eastern Cooperative Oncology Group (ECOG) performance status, laboratory values, or prior cancer diagnoses
- Patients already enrolled on a therapeutic clinical trial will be excluded from this study as to not confound any exploratory outcomes associated with this trial and/or any clinical trials evaluating novel anti-cancer therapies unless granted permission by the local site principal investigator (PI)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm I (ROAR-LCS)
Patients complete in person physical therapy sessions during weeks with regularly scheduled clinic visits, at first session after surgery, and the final session.
These sessions include 10 minutes of a cardiovascular warm up followed up core exercise and resistance training.
Patients also complete virtual physical therapy sessions in a similar fashion during weeks in between regularly scheduled clinic visits.
Patients complete 6-8 sessions prior to surgery and 12 sessions total (over 3-4 months).
Patients receive a portable exercise peddler and resistance bands for at home exercise.
Patients complete the exercises at home as instructed during their sessions, at first weekly then increased to twice then three times weekly depending upon tolerance.
Patients also complete progressive muscle relaxation exercises during a guided virtual session once weekly and at home individually 3-5 times per week.
Patients also undergo blood sample collection on study.
|
Realizar coleta de sangue
Outros nomes:
Estudos auxiliares
Complete exercises at home
Receive portable exercise peddler and resistance bands
Complete assigned exercises
Complete physical therapy sessions
Outros nomes:
Complete progressive muscle relaxation
|
|
Experimental: Arm II (BeFitMe)
Patients receive access to the BeFitMe app on their smartphone and an Apple watch and exercise flip book for 9 months.
Patients are assigned exercises, lasting at least 3 minutes, and receive access to self guided exercise videos.
Patients receive motivational text messages to encourage their completion of the exercises once daily.
Patients track their exercise and step counts using the app.
Patients also undergo blood sample collection on study.
|
Realizar coleta de sangue
Outros nomes:
Estudos auxiliares
Complete exercises at home
Receive portable exercise peddler and resistance bands
Complete assigned exercises
Receive access to the BeFitMe application
Receive motivational text messages
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence (feasibility)
Prazo: At 12 week follow up session
|
Defined as completion of ≥ 8 of the program sessions (Resiliency and Operative Success among Adults Receiving Lung Cancer Surgery [ROAR-LCS]) and 3 out of the 5 repeated assessments (BeFitMe) at the end of the study period, whichever occurs first.
|
At 12 week follow up session
|
|
Retention (feasibility)
Prazo: Up to 6 months post recruitment
|
Defined as the percentage of participants not lost to follow-up at 12 weeks (pre-operative), post-operative (around 12 weeks), and 6 months post recruitment.
|
Up to 6 months post recruitment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Carolyn J Presley, MD, Ohio State University Comprehensive Cancer Center
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Técnicas de investigação
- Terapêutica
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Terapias mente-corpo
- Terapias complementares
- Terapia comportamental
- Psicoterapia
- Disciplinas e atividades comportamentais
- Reabilitação
- Manipulação de amostras
- Modalidades de fisioterapia
- Terapia de relaxamento
Outros números de identificação do estudo
- OSU-24288 (Outro identificador: Ohio State University Comprehensive Cancer Center)
- NCI-2026-02426 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Carcinoma de células não pequenas de pulmão ressecável
-
Taichung Veterans General HospitalConcluídoCardiotoxicidade | Carcinoma de Pulmão de Células não Pequenas (Termo MeSH: Carcinoma, Non-Small-Cell Lung) | Efeitos Secundários e Reações Adversas Relacionadas com Medicamentos (Termo MeSH) | Inibidor da Tirosina Quinase do EgfrTaiwan
-
Fondazione del Piemonte per l'OncologiaRecrutamentoCâncer de mama | Cancro do ovário | Câncer colorretal | Melanoma (câncer de pele) | Carcinoma de Pulmão de Células não Pequenas (Termo MeSH: Carcinoma, Non-Small-Cell Lung)Itália
-
Novartis PharmaceuticalsRescindidoMelanoma | Avançado EGFR mutante non Small Cell LungCancer (NSCLC) | KRAS G12-MUTANT NSCLC | Câncer de células escamosas esofágicas (SCC) | Cabeça/pescoço SCC | Tumores estromais gastrointestinais avançados (GIST) | NRAS/Braft WT avançado melanoma cutâneoEstados Unidos, Taiwan, Holanda, Canadá, Espanha, Cingapura, Itália, Japão, Coréia do Sul
Ensaios clínicos em Coleta de bioespécimes
-
China-Japan Friendship HospitalAinda não está recrutandoSíndrome do Desconforto Respiratório Agudo | Pneumonia grave adquirida na comunidade
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeRecrutamentoNovos marcadores da função reguladora da condutância transmembrana da fibrose cística (CFTR) no suorFibrose cística | BiomarcadoresBélgica